Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
-
Published:2024-06
Issue:6
Volume:9
Page:103465
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Grinshpun A.,
Ren S.,
Graham N.,
DeMeo M.K.,
Wrabel E.,
Carter J.,
Tayob N.,
Pereslete A.,
Hamilton E.,
Juric D.,
Mayer E.L.,
Tolaney S.M.,
Krop I.E.,
Metzger O.ORCID